Clinical Trials
791
42 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1967
Active, not recruiting
21
2.6%
Completed
468
59.2%
Enrolling By Invitation
6
0.8%
Not yet recruiting
15
1.9%
Recruiting
100
12.6%
Suspended
1
0.1%
Terminated
86
10.9%
Unknown
33
4.2%
Withdrawn
61
7.7%
No approval data available
- Teenagers spending six or more hours daily on social media are twice as likely to exhibit anxiety symptoms and three times as likely to report suicidal ideation compared to those using platforms under one hour daily. - The study tracked 1,066 individuals from age 12 through annual surveys from 2018 to 2025, capturing the rise of modern platforms like TikTok. - Female participants reported higher total social media usage, and the association between high usage and anxiety symptoms was significantly stronger among girls. - Researchers highlight dual mechanisms: social comparison and displacement of real-world prosocial activities, alongside potential reverse causality where distressed youth seek social media for escape.
- Houston Methodist researchers found that brain regions experiencing ARIA-E swelling from Alzheimer's drugs like lecanemab and donanemab showed significantly greater amyloid plaque clearance compared to non-swollen areas. - The study analyzed PET scans from patients with moderate to severe brain swelling and found that 80% showed more substantial amyloid clearing in swollen regions, suggesting ARIA-E may indicate strong local treatment activity. - These findings could reframe ARIA-E from being viewed solely as an adverse side effect to a potential biomarker of therapeutic efficacy in amyloid-targeting treatments. - Researchers propose that the swelling occurs due to increased vascular permeability allowing higher drug concentrations to reach and dissolve amyloid clumps more effectively.
- The SLIM LIVER study demonstrated that semaglutide significantly improved cardiovascular risk biomarkers in people living with HIV and metabolic dysfunction-associated steatotic liver disease (MASLD). - This Phase II trial represents the first clinical study to test semaglutide as a treatment for MASLD specifically in HIV patients, addressing a population at increased cardiovascular risk. - The cardiovascular improvements appeared independent of changes in weight, liver fat, or insulin resistance, suggesting semaglutide has additional protective mechanisms beyond its known metabolic effects. - Results were presented at the 2025 AASLD Liver Meeting, expanding on previous findings that showed semaglutide improved and sometimes completely resolved MASLD in HIV patients.
- Genprex has entered into an exclusive patent license agreement with UTHealth Houston for its REQORSA gene therapy to treat glioblastoma, expanding beyond its established lung cancer applications. - Preclinical studies demonstrated that REQORSA significantly reduced glioblastoma cell viability and suppressed cancer cell migration by restoring TUSC2 expression, a novel tumor suppressor for this deadly brain cancer. - The agreement grants Genprex exclusive commercial rights to REQORSA for glioblastoma, addressing a significant unmet medical need for the most common and aggressive primary brain tumor in adults.
- A phase 1b/2a clinical trial has begun testing EG110A, a modified herpes virus vector that delivers botulinum toxin genes to treat neurogenic bladder in spinal cord injury patients. - Unlike current treatments requiring multiple bladder injections every six months, this innovative gene therapy could potentially provide relief from urinary incontinence for several years with a single procedure. - The 52-week trial is recruiting patients across four U.S. centers, with participants receiving intradetrusor injections at varying dose levels to determine safety, tolerability, and initial efficacy.
- UTHealth Houston researchers launch innovative telerehabilitation trial offering at-home stroke recovery services to uninsured patients in Cameron County, Rio Grande Valley. - The study will test a personalized rehabilitation software called Mobile Rehab, delivering video-based strengthening exercises to stroke survivors through a web platform. - The nine-month randomized trial will enroll 30 stroke patients, combining telerehabilitation with community health worker support to improve functional and mental health outcomes.
- Grace Therapeutics' Phase 3 STRIVE-ON trial of GTx-104, an injectable nimodipine formulation, met its primary endpoint with 19% reduction in clinically significant hypotension compared to oral nimodipine in aSAH patients. - The novel IV formulation demonstrated superior drug delivery, with 54% of GTx-104 patients achieving ≥95% relative dose intensity compared to only 8% with oral nimodipine, alongside reduced ICU stays and ventilator days. - Grace Therapeutics plans to submit New Drug Application (NDA) in first half of 2025, potentially offering the first major innovation in aSAH treatment in nearly 40 years.
• A new review suggests GLP-1 drugs like semaglutide and tirzepatide may offer neuroprotective benefits beyond weight loss and improved insulin sensitivity. • GLP-1 drugs can balance the neurovascular unit, potentially improving cognitive function by reducing brain inflammation associated with obesity. • Research indicates GLP-1 receptor signaling may enhance neuron growth, increase astrocytes, and reverse inflammation by modulating microglia activity. • Clinical trials are underway to assess the efficacy of semaglutide in treating Alzheimer’s disease, with results from the EVOKE trial expected in 2025.
- A study published in _Annals of Neurology_ highlights the effectiveness of magnetic resonance-guided laser interstitial thermal therapy (MRgLITT) for drug-resistant epilepsy caused by periventricular nodular heterotopia (PNVH). - The MRgLITT procedure precisely targets and destroys abnormal brain tissues responsible for seizures, guided by detailed brain mapping using stereo-electroencephalography (SEEG). - Results showed that up to 80% of patients with localized abnormal brain tissue became seizure-free after the SEEG-guided MRgLITT procedure, offering a life-changing option. - This minimally invasive approach offers a potential game-changer for individuals struggling with medication-resistant epilepsy, avoiding more invasive brain surgeries.
• AstraZeneca and Moffitt Cancer Center are collaborating to accelerate cell therapy development, focusing on CAR T and TCR T therapies for solid tumors. • SWOG Cancer Research Network developed a risk prediction model to identify cancer patients at high risk for emergency room visits during clinical trials. • A national clinical trial is launched by UC San Francisco to repurpose existing drugs for treating traumatic brain injury (TBI), addressing a critical unmet need. • The Ohio State University initiates clinical trials for HOSU-53, a novel DHODH inhibitor, in partnership with Jabez Biosciences, targeting cancer metabolism.
